Zydus Cadila’s Covid-19 vaccine, ZyCoV-D, has been approved for emergency use in India to be administered to people aged 12 and above. On Friday, the Drug Controller General of India (DCGI) granted Zydus Cadila an Emergency Use Authorization (EUA) for ZyCoV-D.
The Department of Biotechnology (DBT) said it is the world’s first and India’s first DNA-based vaccine for COVID-19 to be administered in humans, including children and adults aged 12 and above.
ZyCoV-D is a three-dose vaccine. It will be administered on the first day, the 28th day, and the 56th day.
Zydus Cadila claims that ZyCoV-D works against newer viral strains, particularly the highly contagious Delta form.
After Covishield from the Serum Institute of India, Covaxin from Bharat Biotech, Sputnik V from Russia, and vaccines from Moderna and Johnson & Johnson, ZyCov-D is the sixth vaccine to receive emergency use authorization in India.